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Abstract
Theranostic agents are critical for improving the diagnosis and treatment of non-Hodgkin Lymphoma (NHL). The
peptidomimetic LLP2A is a novel peptide receptor radiotherapy candidate for treating NHL that expresses the activated
a4b1 integrin. Tumor-bearing dogs are an excellent model of human NHL with similar clinical characteristics, behavior, and
compressed clinical course. Canine in vivo imaging studies will provide valuable biodistribution and affinity information that
reflects a diverse clinical population of lymphoma. This may also help to determine potential dose-limiting radiotoxicity to
organs in human clinical trials. To validate this construct in a naturally occurring model of NHL, we performed in-vivo
molecular targeted imaging and biodistribution in 3 normal dogs and 5 NHL bearing dogs.
99mTc-LLP2A-HYNIC-PEG and
99mTc-LLP2A-HYNIC were successfully synthesized and had very good labeling efficiency and radiochemical purity.
99mTc-
LLP2A-HYNIC and
99mTc-LLP2A-HYNIC-PEG had biodistribution in keeping with their molecular size, with
99mTc-LLP2A-
HYNIC-PEG remaining longer in the circulation, having higher tissue uptake, and having more activity in the liver compared
to
99mTc-LLP2A-HYNIC.
99mTc-LLP2A-HYNIC was mainly eliminated through the kidneys with some residual activity.
Radioactivity was reduced to near-background levels at 6 hours after injection. In NHL dogs, tumor showed moderately
increased activity over background, with tumor activity in B-cell lymphoma dogs decreasing after chemotherapy. This
compound is promising in the development of targeted drug-delivery radiopharmaceuticals and may contribute to
translational work in people affected by non-Hodgkin lymphoma.
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Introduction
The a4b1 integrin is widely expressed on Non-Hodgkin’s
Lymphoma (NHL) cells [1,2], and provides a new target for agents
capable of selectively binding to this site. The integrin normally
plays a role in lymphocyte homing, and passage of the
lymphocytes through the endothelial wall, to sites of inflammation,
and may contribute to dissemination of NHL [3,4]. It has recently
been identified as a target for both imaging and treatment of
relapsed and refractory NHL using imaging dosimetry of the
therapeutic target, CD20 [5]. However, new targeted agents are
needed for first line therapy of NHL by a high affinity
peptidomimetic ligand. The peptidomimetic LLP2A(N-[[4-[[[(2-
ethylphenyl)amino]carbonyl]amino]phenyl]acetyl]-N
e-6-[(2E)-1-
oxo-3-(3-pyridinyl-2-propenyl)]-L-lysyl-L-2-aminohexanedioyl-(1-
amino-1-cyclohexane)carboxamide), is comprised of D- and
unnatural amino acids that are resistant to proteases in human
plasma. Theranostic agents are critical for improving the diagnosis
and treatment of non-Hodgkin Lymphoma (NHL). NHL is a very
radiosensitive tumor making it ideal for development of targeted
radiotherapeutic drugs. Radioimmunotherapy (RIT) has revolu-
tionized the imaging and treatment of relapsed and refractory
NHL using imaging dosimetry of the therapeutic target, CD20 [5].
However, new targeted agents are needed for first line therapy,
patients who do not respond to currently available therapies, and
for those who relapse after RIT. Reversible bone marrow
suppression is the dose limiting toxicity for Y-90 Ibrutumomab
tiuxetan and I-131 tositumomab [6]. RIT with MAb to other
target provide therapeutic alternatives as well but marrow
suppression continues to be the limiting toxicity [7]. Peptide
receptor radiation therapy (PRRT) is an alternative strategy for
delivering diagnostic and therapeutic agents to tumors [8]. The
peptidomimetic LLP2A (N-[[4-[[[(2-ethylphenyl)amino]carbony-
l]amino]phenyl]acetyl]-N
e-6-[(2E)-1-oxo-3-(3-pyridinyl-2-prope-
nyl)]-L-lysyl-L-2-aminohexanedioyl-(1-amino-1-cyclohexane)car-
boxamide), is comprised of D- and unnatural amino acids that are
resistant to proteases in human plasma [9]. LLP2A has a high
affinity to activated a4b1 on lymphoma cells, and the integrin has
been found to be important in tumor growth and metastasis [4].
LLP2A is a novel PRRT candidate for treating NHL that
expresses the activated a4b1 integrin [9]. LLP2A is a novel PRRT
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34404candidate for treating NHL that expresses the activated a4b1
integrin [9].
Theranostic agents are critical for improving the diagnosis and
treatment of Non-Hodgkin’s Lymphoma (NHL) [3]. NHL is a very
radiosensitive tumor making it ideal for development of targeted
radiotherapeutic drugs. Radioimmunotherapy (RIT) has revolu-
tionized the imaging and treatment of relapsed and refractory
NHL using imaging dosimetry of the therapeutic target, CD20 [5].
However, new targeted agents are needed for first line therapy,
patients who do not respond to currently available therapies, and
for those who relapse after RIT. Reversible bone marrow
suppression is the dose limiting toxicity for Y-90 Ibrutumomab
tiuxetan and I-131 tositumomab [6]. RIT with MAb to other
target provide therapeutic alternatives as well but marrow
suppression continues to be the limiting toxicity [7]. Peptide
receptor radiation therapy (PRRT) is an alternative strategy for
delivering diagnostic and therapeutic agents to tumors [8].
Nanotechnology theranostics have been developed as a multi-
faceted approach to countering the intratumor and biological
intertumor variability found in cancer patients. Ligands are often
used to provide targeting of the carrier to the designated site, such
as small molecules, peptides, peptidomimetics, carbohydrates,
monoclonal antibodies, and DNA/RNA aptamers [10]. The use
of smaller particles less than 100 nm will reduce clearance by the
reticuloendothelial system [11]. We aimed to develop an agent
with theranostic potential that is small enough in size to penetrate
into cells, and has biodistribution properties that allow a good
therapeutic index.
99mTc-LLP2A-HYNIC, comprised of peptido-
mimetic and radiopharmaceutical, is very small (,1 nM), which
allows it to overcome many of these obstacles to tumor targeting.
Targeted therapies are hindered in translation from the bench
to the clinic by pre-clinical studies that do not accurately represent
the range of conditions found in naturally occurring tumors in
immune competent hosts. Tumor-bearing dogs are an excellent
model of human NHL with similar clinical characteristics,
behavior, and compressed clinical course [12,13]. The natural
inhomogeneity of the canine model and rapid progression of
disease allow realistic testing of the behavior of a new drug in vivo.
The biological variations in expression of integrins are also more
likely to reflect the clinical situation than those of cell lines. LLP2A
has been tested in vitro using canine cell lines and tissue samples
from affected animals, and has been found to have good affinity to
canine lymphoma, although less than that reported in cell lines
and xenografts of human cell lines in mice [9,14,15]. Constructs
including
111In-LLP2A-DOTA, and optical imaging probes
(LLP2A-Cy5.5) have been used to confirm affinity of LLP2A to
xenografts in mice [14,16]. Canine in vivo imaging studies will
provide valuable biodistribution and affinity information that
reflects a diverse clinical population of lymphoma. This may also
help to determine potential dose-limiting radiotoxicity to organs in
human clinical trials.
To validate this construct in a naturally occurring model of
NHL, we performed in-vivo molecular targeted imaging and
biodistribution in 3 normal dogs and 5 NHL bearing dogs. From
discovery of the optimum high-affinity peptide for naturally
occurring tumors, to data closely paralleling a human phase 0/1
clinical trial, this study provides baseline information for further
development of LLP2A as a new theranostic agent. The safety and
toxicity information in tumor-bearing dogs, and dosimetry
predictions for trials of the radiotherapeutic agent, will be
extremely valuable in planning human clinical trials. A novel
PRRT therapy could improve the treatment response of NHL
patients with high expression of the a4b1 integrin.
Materials and Methods
Preparation of LLP2A-HYNIC
Synthesis of LLP2A-HYNIC. LLP2A-HYNIC was designed
to have HYNIC attached to the side chain of Lys, and two
hydrophilic linkers betweenLLP2A and Lys(HYNIC). The
synthetic scheme is shown in Figure 1A. The synthesis was
performed on rink amide MBHA resin using a similar approach as
we previously reported [14]. 6-Boc-HNA-OSu (3 eq. to resin,
from Solulink, Inc, San Diego, CA) was coupled to the e-amino
group of lysine in presence of diisopropylethylamine (6 eq.). The
cleaved crude products were purified by semi-preparative
reversed-phase high performance liquid chromatography (RP-
HPLC) and lyophilized to give a white powder. The purity was
determined to be .95% on analytical HPLC. The identity of the
compounds was confirmed by Matrix-assisted laser desorption/
ionization time of flight mass spectrometry (MALDI-TOF MS):
[M+Na
+]: 1556.78 (calculated: 1556.79).
Preparation of LLP2A-HYNIC-PEG conjugate. A D-Lys
was added to the C-terminal of LLP2A-HYNIC, therefore its e-
amino group could be used as the site for PEGylation (Figure 1B).
The synthesis of LLP2A-HYNIC(Fmoc)-D-Lys is similar to
LLP2A-HYNIC except an additional Fmoc-D-Lys(Boc) as the
first amino acid was attached to the rink amide resin, and 6-Fmoc-
HNA-OSu (Solulink, Inc, San Diego, CA) was used to replace 6-
Boc-HNA-OSu. 10,000-Da PEG was selected according to
a previous study [14]. PEGylation was achieved with 10,000-Da
mPEG-succinimidyla-methylbutanoate (PEG-NHS ester, Nektar
Therapeutics AL Corporation, Huntsville, AL) using the same
approach as we previously reported [14].
Radiopharmaceutical preparation–
99mTc-LLP2A-
HYNIC. In a typical reaction, [
99mTc]technetium
pertechnetate (
99mTcO4; GE Healthcare, Sacramento, CA;
29 mCi) in saline (150 mL) was combined with 1 M NH4OAc,
(pH 5.2, 50 mL), LLP2A-HYNIC (MW 1534; 0.45 mg, or
290 nmol) in 0.25 M NH4OAc, pH 5.2 (45 mL), tricine (4.5 mg)
in H2O (45 mL), and SnCl2N2H2O (25 mg) in 10 mM HCl (5 mL).
The solution was incubated on a heating block at 60–70uC for
1 hour, and purified by C18 solid phase extraction (SPE; ORTG,
Oakdale, TN). Purified
99mTc-LLP2A-HYNIC (20 mCi) in 1:1 (v/
v) ethanol:saline eluent (0.25 mL) was formulated with unlabeled
LLP2A-HYNIC and PBS to a final concentration of 2 mCi/
0.2 mg/mL, sterilized by 0.22 mm filtration, and dosed at 0.05 mg
(33 nmol) per kg body weight. Thin layer chromatography (TLC)
was performed to evaluate radiochemical purity of the product.
Radiopharmaceutical preparation–
99mTc-LLP2A-HYNIC-
PEG. LLP2A-HYNIC-PEG (MW 12,095) was radiolabeled
similarly, and dosed at 0.4 mg (33 nmol) per kg body weight.
Animal Care and Use
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals by the National Research Council. This
study was conducted with the approval of the University of
California, Davis Animal Care and Use Committee, protocol
10806 and 12349. All efforts were made to minimize stress during
imaging.
Safety and Toxicity Assays in Mice
Before initiating in vivo tests in dogs using LLP2A-HYNIC, an in
vivo study using mice was conducted to assess safety. LLP2A-
HYNIC was injected intraperitoneally into mice at 2 doses
(10 mg/mouse and 100 mg/mouse). There were 5 and 6 mice in
each treatment, respectively. Mice were weighed daily for 1 week.
LLP2A in Canine Non-Hodgkin Lymphoma
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20 days post injection. For the mouse safety study, weight was
modeled as a function of time with an autoregression correlation
structure to account for correlation of measurements across time.
To account for varying starting weights among mice, each mouse’s
starting weight was subtracted from subsequent weights and the
model was fit without an intercept. These analyses were conducted
using Proc Mixed in SAS Version 9.2. The pooled platelet count
and white blood cell count were graphically examined.
Biodistribution
Imaging equipment and software. All dogs were imaged
with a Gamma camera (Technicare Omega 500, Solon, Ohio, or
IS2, Ottawa, Ontario). Images were obtained of the whole body in
overlapping segments, in right lateral, left lateral, and sternal
recumbency. Images were obtained to 200,000 counts, with
a 2566256 bit matrix and 16-bit depth. A camera standard of
200 uCi in 10 mL of water was included in each image to ensure
stable measurements over the scan period. Camera sensitivity was
determined by placing the camera standard 30 cm from the
detector and scanning for 1 minute. This calibration factor was
used to convert individual organ emission counts to mCi.
Normal dog biodistribution. All 3 dogs were mixed breed
dogs and after physical examination were clinically normal. The 3
normal dogs were imaged using both
99mTc-LLP2A-HYNIC and
99mTc-LLP2A-HYNIC-PEG, given 24 hours apart, to determine
normal biodistribution and imaging characteristics of the agents.
The labeled peptide (10 mCi on 0.05 mg/kg
99mTc-LLP2A-
HYNIC or 0.4 mg/kg
99mTc-LLP2A-HYNIC-PEG) was injected
by slow bolus into a catheterized cephalic vein, and the dogs were
monitored for adverse reactions in heart rate, respiratory rate,
temperature, and blood pressure at 0, 15, 30, 60, 120, and
240 minutes. Images of the whole body in orthogonal planes were
acquired at 2 hours, 4 hours, and 6 hours after injection.
Complete blood counts and serum biochemistry were performed
before and after imaging.
Imaging of dogs affected with lymphoma. 5 dogs with
naturally occurring lymphoma were imaged using the above
protocol. Three dogs had B-cell lymphoma and 2 dogs had T-cell
lymphoma. Dogs were staged by cytologic evaluation of fine
needle aspirates of the single affected lymph node, or
a representative lymph node in diffuse disease. Abdominal
ultrasound, bone marrow aspirates, and thoracic radiographs
were also performed.
99mTc-LLP2A-HYNIC was used in 2 dogs
with B-cell lymphoma, 1 of which was imaged before and after the
initial course of chemotherapy (9 weeks).
99mTc-LLP2A-HYNIC-
PEG was used in 3 dogs, 1 B- and 2 T-cell lymphoma, two of
which were imaged both before and after chemotherapy (6 weeks
and 8 weeks). Chemotherapy consisted of prednisone, vincristine,
cyclophosphamide, and L-asparaginase. Two dogs had whole
body computed tomography (CT) performed. One dog had pre-
and postcontrast (Isovue 370, Bracco Diagnostics Inc., Princeton,
NJ) CT imaging pretreatment and post-treatment, and one dog
had non-contrast enhanced CT imaging performed pretreatment.
CT scans were performed at 120 kVp and 150 mA with 7 mm
collimation using a helical scanner (GE Prospeed, General Electric
Co., Milwaukee, WI).
Whole body biodistribution. Blood samples were obtained
from all dogs at time 0, 15, 30, 60, 120, 240, and 360 minutes to
document clearance of the radiopharmaceutical. 2 mL of blood
were drawn into a heparinized syringe. Aliquots of 0.5 mL
samples were processed with a well counter (PerkinElmer Wizard
1470, Covina, California) calibrated to
99mTc. The radioactivity in
blood was calculated by using total blood volume based on body
weight, and was decay-corrected [17]. In addition, radioactivity
readings of the whole body were taken using a handheld monitor
at 1 m distance from the dog at time 0, 15, 30, 60, 120, 240,
360 minutes, and 24 hours.
All dogs were held overnight in a protected area with
institutionally approved radiation safety protocols. Dogs were
released from the facility after whole body radiation levels were
Figure 1. Synthesis of LLP2A-HYNIC and LLP2A-HYNIC-PEG. A. Synthetic approach for LLP2A-HYNIC. B. Synthetic approach of LLP2A-HYNIC-
PEG.
doi:10.1371/journal.pone.0034404.g001
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at 1 m.
Organ uptake of LLP2A. For all scintigraphic studies,
regions of interest (ROI) were drawn around each organ of
interest (liver, lung, bone marrow, lymph node, gastrointestinal
tract, kidney, salivary gland) on images acquired at 2 hours,
4 hours, and 6 hours after injection. ROIs were drawn on the
2 hour images and duplicated for the opposite lateral projection
and subsequent time points, and adjusted for altered patient
position. ROIs were also drawn in the temporal muscle of the head
(background correction for lymph nodes and salivary gland),
longissimus thoracis muscles (background correction for bone
marrow activity in the thoracic spine), the iliocostalis muscles
(background correction for liver and kidney), and combined
abdominal musculature (background correction for
gastrointestinal tract). The counts and pixels of each ROI were
obtained using imaging software (Nuclear Mac, Scientific Imaging
Inc., Crested Butte, CO; or Osirix Imaging Software, Version
2.7.5; http://www.osirix-viewer.com/).
Organs that were clearly delineated on conjugate projections
(liver, GI, bone marrow, lung) were measured using the geometric
mean method, and smaller or peripherally located organs (kidney,
mandibular lymph nodes, salivary gland) were measured using the
effective point source method [18]. Depth for depth correction was
measured on orthogonal images. Lung activity was measured
using an ROI in a posterior region and normalized to the total
pixels of the lung [19]. Attenuation correction was achieved using
the equation for
99mTc in soft tissue [20]. Background correction
was used in all calculations [18]. Lung activity was measured using
an ROI in a posterior region and normalized to the total pixels of
the lung [19]. Attenuation correction was achieved using the
equation for
99mTc in soft tissue [20]. Background correction was
used in all calculations. Camera sensitivity was measured using the
camera standard. Percent injected dose and organ:muscle ratio
were calculated for each imaging study at each time point.
Imaging results are presented in graphical format as percent
injected dose for each organ evaluated, as well as organ:muscle
ratios.
Blood levels (percent injected dose) over time are provided in
Table S1. Whole body activity (mR/hr) data is in Table S2 and
the biodistribution data are provided in Table S3. The specific
activity of each dose is provided in Table S4.
Results
Safety and Toxicity Assay in Mice
At the 10 ml/mouse dosage, weight significantly differed across
days (F7,13=3.86, p=0.017). Weight significantly decreased the
first day after injection (t=23.09, p=0.016). However, after the
first day, weight increased and did not differ significantly from the
starting weight on any subsequent day (Figure 2A). At the 100 ml/
mouse dosage, weight did not differ from the starting weight at any
time (F7,14=0.78, p=0.616; Figure 2B). White blood cell counts
and platelet counts also remained within normal ranges until day
20 (data not shown).
Radiopharmaceutical preparation.
99mTc-LLP2A-
HYNIC and
99mTc-LLP2A-HYNIC-PEG were produced with
mean yields of 67 (610)% and 30 (68)%, respectively, and the
radiochemical purity of every dose was .95%. The mean injected
dose per dog was 7.7 mCi (range 2.8–10.7 mCi), or 0.41 mCi/kg
(range 0.15–0.84). The mean specific activity of
99mTc-LLP2A-
HYNIC injected was 8.95 mCi/mg (SD 2.38), and of
99mTc-
LLP2A-HYNIC-PEG was 1.29 mCi/mg (SD 0.59).
Biodistribution
Blood and Whole body activity. Both
99mTc-LLP2A-
HYNIC and
99mTc-LLP2A-HYNIC-PEG had high activity, with
the pegylated form having a greater whole body activity initially.
The mean whole body activity of
99mTc-LLP2A-HYNIC at
5 minutes post-injection was 0.5 mR/h (range 0.2–0.8), and the
mean whole body activity of
99mTc-LLP2A-HYNIC-PEG was
1.1 mR/h (range 1–1.5). At 360 min the mean whole body
activity of
99mTc-LLP2A-HYNIC had decreased to 0.13 mR/h
(range 0.03–0.05) and that of
99mTc-LLP2A-HYNIC-PEG was
0.19 mR/h (range 0.02–0.4). By 24 hours the activities were
similar for the nonpegylated and pegylated forms (0.04 and
0.05 mR/h, respectively).
The Percent Injected Dose (PID) in the blood declined over
time in both normal (Figure 3A) and NHL (Figure 3B) dogs. The
trajectory of the decline was similar in both groups. Normal dogs
sequentially received each LLP2A form. For these dogs,
99mTc-
LLP2A-HYNIC-PEG consistently remained in the blood at higher
levels than the form without PEG for a given dog (Figure 3A).
NHL dogs received only one of the two LLP2A forms thus
precluding a paired comparison of the PID trajectories of each
form. Nevertheless, NHL dogs receiving the
99mTc-LLP2A-
HYNIC-PEG generally had higher PID levels than those receiving
the
99mTc-LLP2A-HYNIC form (Figure 2). This difference was
most apparent in the first hour after injection.
The activity of one form of LLP2A was evaluated in three dogs
(L2, L3, L5) before and after chemotherapy treatment. Blood PID
was higher in these dogs after chemotherapy (Figure 3B). The one
exception was with L2 at 240 and 360 minutes after injection; PID
was nearly equivalent at these times before and after chemother-
apy. Whole body activity also declined over time but the patterns
observed for blood PID were less evident (Figure 3C). Whole body
activity was less than 0.4 mR/hr at 6 hours post injection.
Finally, we compared mean blood PID for
99mTc-LLP2A-
HYNIC and
99mTc-LLP2A-HYNIC-PEG over time in normal,
pre-chemotherapy and post-chemotherapy dogs (Figure 3D).
Mean PID was consistently higher with
99mTc-LLP2A-HYNIC-
PEG than
99mTc-LLP2A-HYNIC for all dogs. For
99mTc-LLP2A-
HYNIC, post-chemotherapy dogs generally had higher PID than
normal or pre-chemotherapy dogs, but this generalization did not
hold for
99mTc-LLP2A-HYNIC-PEG.
Imaging biodistribution. Organ:muscle ratios of organs in
normal dogs at 2 hours were slightly higher than those in NHL
dogs (Figure 4A). Mean(6SE) organ-muscle ratios and percent
injected dose in organs at 2 and 6 hours after injection had slightly
higher uptake in tissues, particularly the lung, parotid salivary
gland, and kidney. At 6 hours, more
99mTc-LLP2A-HYNIC-PEG
remained in the tissues compared to
99mTc-LLP2A-HYNIC
including the bone marrow, GI tract, parotid salivary gland, and
kidney (Figure 4B). The highest PID for both forms of the peptide
at 2 and 6 hours were the liver and lung, which represented the
largest organs (Figure 4C, 4D).
99mTc-LLP2A-HYNIC-PEG had
higher activity in the lung at both time points, which in part likely
reflected the higher residual activity in the blood.
NHL dogs had slightly lower organ:muscle ratios at 2 hours,
and more significantly lower ratios at 6 hours. This trend was less
evident in PID where the normal and NHL dogs were more
similar across organs. NHL dogs had a similar increased
organ:muscle ratio with
99mTc-LLP2A-HYNIC-PEG than
99mTc-LLP2A-HYNIC except for in the kidneys.
Each dog had tissue sampling performed by fine needle aspirate,
biopsy, or excision and samples were reviewed by a veterinary
pathologist. Tissues in each dog that were suspected to be affected
by NHL were sampled, in addition to a representative lymph node
LLP2A in Canine Non-Hodgkin Lymphoma
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contain lymphoma included bone marrow (L1), gastrointestinal
lymph nodes (L2), kidney (L1), liver (L2), mandibular lymph node
(L1–5), and retropharyngeal lymph node (L1, L2) (Figure 5). In
dogs L4 and L5, the mandibular lymph node was the only site of
T-cell lymphoma. Images were compared with affected tissues and
the percent injected dose was calculated. Alternate imaging
confirmation of affected tissues was performed for affected
gastrointestinal lymph nodes, kidney, liver, and retropharyngeal
lymph nodes (ultrasonography), and two dogs with enlarged
mandibular lymph nodes (CT). B-cell lymphoma affected tissues
had higher activity compared to background compared with T-cell
lymphoma (Figure 6A). Activity decreased in most tissues post-
chemotherapy compared to pre-chemotherapy. The highest
organ:muscle ratio (7.00) occurred in a kidney affected with
lymphoma (Figure 6B). This activity was higher than in the
unaffected kidney in the same dog (5.27). The affected liver also
decreased in activity post-chemotherapy (Figure 6C, 6D).
Incidental uptake was seen in the parotid salivary gland in all
dogs. Two affected dogs injected with
99mTc-LLP2A-HYNIC-
PEG had uptake in the stomach. Serum samples taken from these
dogs during the study were tested using HPLC and verified that
the radiopharmaceutical had .95% purity.
Heart rate, temperature, respiratory rate, and mucus membrane
color of dogs did not change significantly during the period after
radiopharmaceutical injection. Two dogs receiving the pegylated
form of LLP2A had mild, transient increases in mean blood
pressure at 5 and 15 minutes post-injection. One dog with T-cell
lymphoma had leukopenia and anemia after the second imaging
time point. One dog with B-cell lymphoma had slight progression
of increased BUN and creatinine, and one had a mild increase in
liver enzymes.
Discussion
99mTc-LLP2A-HYNIC-PEG and
99mTc-LLP2A-HYNIC were
successfully synthesized and had acceptable labeling efficiency and
excellent radiochemical purity.
99mTc-LLP2A-HYNIC and
99mTc-LLP2A-HYNIC-PEG had biodistribution in keeping with
their molecular size, with
99mTc-LLP2A-HYNIC-PEG remaining
longer in the circulation, having higher tissue uptake, and having
more activity in the liver compared to
99mTc-LLP2A-HYNIC.
99mTc-LLP2A-HYNIC was mainly eliminated through the kidneys
with some residual activity. Radioactivity was reduced to near-
background levels at 6 hours after injection. In NHL dogs, tumor
showed moderately increased activity over background, with
tumor activity in B-cell lymphoma dogs decreasing after
chemotherapy.
The slight variability in labeling efficiency resulted in slightly
varying total doses of activity to each dog, however the activity was
more than sufficient for imaging. The total body dose decayed and
cleared in 24 hours providing a practical time frame for imaging
as well as the release of the animal from radiation protected
facilities. There was uptake of the compounds into the parotid
salivary gland in all dogs, and in the stomach of two dogs. When
imaging with
99mTcO4-, these tissues uptake the radionuclide
because of its negative charge. The increased signal in these organs
may have been due to small amounts of
99mTcO4-, although 95%
was bound according to HPLC testing of the pre-injection dose,
and in the serum of the two dogs with gastric uptake, indicating
that there was little dissociation of
99mTc from the LLP2A in vivo.
No abnormalities of the stomach were detected on abdominal
ultrasound. Free
99mTcO4- expression of the target in stomach
and salivary glands would be less likely, however has not been
studied. A target mediated drug disposition may have been further
studied with a dose-escalation study, however additional dogs with
NHL were not available.
Both forms of LLP2A had good bioavailability with adequate
blood activity and minor tissue activity in normal organs. As
expected, the addition of 10,000 MW PEG to the compound
increased bioavailability by increasing the size of the molecule and
preventing rapid clearance through the renal system [21,22]. This
was evidenced by the higher circulating blood levels compared to
the non-pegylated form. There was also some increased activity in
the tissues of dogs injected with
99mTc-LLP2A-HYNIC-PEG,
which is likely due to increase in charge of the molecule [14], as
Figure 2. Safety assay of LLP2A-HYNIC in mice. A. Weight (g) of five mice treated with 10 mg/100mL LLP2A-HYNIC over 8 days. B. Weight (g) of
six mice treated with 100 mg/100mL LLP2A-HYNIC over 8 days.
doi:10.1371/journal.pone.0034404.g002
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34404well as the possibility of increased non-specific binding. In NHL
dogs, there was less activity of each form in tissues compared to
normal dogs, and a trend toward more activity in the blood.
Alterations of lymphocytes in NHL dogs could include increased
activation due to inflammation, and leukopenia secondary to
chemotherapy. LLP2A has mild affinity to normal lymphocytes
which increases with activation [9,15]. Increased activity in the
blood of NHL dogs could be caused by non-specific binding of
activated leukocytes, since no dog had documented leukemia at
the time of imaging. This in turn could reduce the bioavailability
of the compound to tissues.
There was moderate normal tissue uptake of
99mTc-LLP2A-
HYNIC-PEG in the bone marrow, GI tract, liver, lung, salivary
gland, kidney, and mandibular lymph node. This was less
apparent with
99mTc-LLP2A-HYNIC where the liver, kidney,
and mandibular lymph node had a lesser degree of uptake. Uptake
in normal tissues was less pronounced in the affected dogs in all
organs except the kidney, which is the major route of excretion of
the radiopharmaceutical. The increased activity in the kidney at
6 hours compared to other organs likely indicates a degree of
binding to the renal tubules. This may be caused by the charge of
the radiopharmaceutical, which in PEGylated forms has been
shown to increase renal and hepatic retention [23]. The activity in
the GI tract also indicates that biliary excretion may occur,
however this was less apparent in affected dogs.
Figure 3. Blood clearance of
99mTc-LLP2A-HYNIC and
99mTc-LLP2A-HYNIC-PEG in dogs. Normal dogs (N1–N3) had higher % injected dose
(PID) (A) than those with lymphoma (L1–L5) (B). In B and C, open symbols represent pre-chemotherapy and closed symbols represent post-
chemotherapy status. In general
99mTc-LLP2A-HYNIC-PEG had higher blood radioactivity than
99mTc-LLP2A-HYNIC. (C). Whole body dose of dogs with
lymphoma at 1 m declined to background levels by 24 hours after administration. (D). Mean Percent injected dose (PID) of
99mTc-LLP2A-HYNIC
(triangles) and
99mTc-LLP2A-HYNIC-PEG (stars) in blood over time for pre- and post-chemotherapy lymphoma dogs and in normal dogs.
doi:10.1371/journal.pone.0034404.g003
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34404The spleen is an organ commonly affected by lymphoma in
dogs, as was found in all B-cell lymphomas included in this study.
However, the spleen was not visible on any image and precluded
its inclusion in the measurements. The canine spleen is a long, flat
organ, that when imaged in lateral recumbency is not in a position
that can overcome the background of liver and GI tract.
Radiographs of the abdomen were used to correlate the positions
of organs on the scintigraphic images, and a discrete signal was not
appreciated.
Tumor-affected tissues had increased activity compared to most
normal organs and compared to background signal. Three dogs
with high grade B-cell lymphoma showed higher activity
compared with the two dogs with intermediate and indolent T-
cell lymphoma. LLP2A has been shown to target T-cell lymphoma
Figure 4. Biodistribution patterns of
99mTc-LLP2A-HYNIC and
99mTc-LLP2A-HYNIC-PEG in normal dogs and dogs with lymphoma
(unaffected tissues) prior to chemotherapy treatment. Mean(6SE) organ:muscle ratios of
99mTc-LLP2A-HYNIC and
99mTc-LLP2A-HYNIC-PEG at
2 hours post injection (A) and 6 hours post injection (B).Percent injected dose (PID) of
99mTc-LLP2A-HYNIC and
99mTc-LLP2A-HYNIC-PEG at 2 hours
post injection (C) and 6 hours post injection (D). Gastrointestinal tract (GI), mandibular lymph node (MLN), popliteal lymph node (PLN).
doi:10.1371/journal.pone.0034404.g004
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difference causing reduced affinity of LLP2A to canine T-cell
lymphoma. There may also be an effect of lower grade tumors
expressing less activated alpha4-beta1 integrin on the cell surface.
The kidney affected with lymphoma had the highest activity of
the tumor tissues, and was increased compared to the contralateral
kidney in the same dog (L1). The radiopharmaceutical used was
99mTc-LLP2A-HYNIC, which tends to have higher renal activity
than
99mTc-LLP2A-HYNIC-PEG. The second dog receiving
99mTc-LLP2A-HYNIC with unaffected kidneys (L3) had similar
renal activity to the normal kidney in L1. Although the renal PID
for this form was higher than
99mTc-LLP2A-HYNIC-PEG, the
tumor affinity was higher still.
The mild changes in blood pressure and lack of other change in
vital signs indicate safety in the peri-injection period. The dogs
with mild changes on CBC and biochemistry were receiving
chemotherapy concurrently, making it difficult to attribute
changes to the LLP2A constructs. The normal dogs had no
changes in blood parameters. More data may be needed to detect
any adverse effects, however there were no significant acute or
chronic changes.
Affinity to tissues previously affected by NHL to
99mTc-LLP2A-
HYNIC and
99mTc-LLP2A-HYNIC-PEG decreased post-chemo-
therapy. This supports the specificity of the radioligand to canine
lymphoma and the alpha4-beta1 integrin. The peptidomimetic
has the potential to provide targeted drug delivery to tumor, as
well as serving as an imaging marker of response to therapy. As has
been done with other radiopharmaceuticals, a test dose may be
administered to verify tumor affinity to the ligand and to estimate
tumor and whole body dose [24]. To date, this has not been
performed in veterinary medicine, in part because of a lack of
Figure 5. Biopsy proven tissues affected with lymphoma imaged with
99mTc-LLP2A pre- and post-chemotherapy. Tissues have
increased activity over background, primarily in the large cell B-cell lymphoma dogs. Activity in these tissues decreased post-chemotherapy. Tissues
without a post-treatment measurement were not available for sampling. Gastrointestinal tract (GI), mandibular lymph node (MLN), popliteal lymph
node (PLN), B-cell lymphoma (B), T-cell lymphoma (T).
doi:10.1371/journal.pone.0034404.g005
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the future [25].
In summary,
99mTc-LLP2A-HYNIC-PEG and
99mTc-LLP2A-
HYNIC are safe in normal dogs and those with NHL. The
radiopharmaceutical is capable of targeting high grade B-cell
canine lymphoma-affected tissue, and affinity decreases post-
chemotherapy. This compound is promising in the development of
targeted drug-delivery radiopharmaceuticals and may contribute
to translational work in people affected by Non-Hodgkin
lymphoma.
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